Semaglutide cuts alcohol cravings but not daily drinks in Phase II trial
A once-weekly injection of semaglutide could cut alcohol cravings and reduce the amount someone living with alcohol use disorder (AUD) …
A once-weekly injection of semaglutide could cut alcohol cravings and reduce the amount someone living with alcohol use disorder (AUD) …
Selkirk Pharma has introduced a paradigm-shifting service, ClinFAST, for ensuring rapid small-volume clinical study materials delivery. The service is designed to …
Alto Neuroscience has reported positive outcomes from the interim analysis of its double-blind Phase IIb trial of oral ALTO-300, as …
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses …
China has seen a rise in ongoing clinical trials for the past few years which has now surpassed the US, …
US-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III …
GenSight’s gene therapy treatment for patients living with Leber hereditary optic neuropathy (LHON) has demonstrated sustained efficacy and eyesight improvement …
US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating Fragile X …
US-based biotechnology company Rallybio has dosed the first subject in a Phase II trial evaluating RLYB212 as a potential treament …
Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that was the takeaway from …
As President Trump’s tariff restrictions are imposed on China, the pharmaceutical industry has been deciphering how it will be impacted …
A US federally funded Phase II challenge trial investigating AbViro’s sole pipeline candidate, AV1, will see 84 patients infected with …
Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the world due to factors such …
Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years …
Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it …